White House's new tariffs on imported medicines aim to reshape US pharmaceutical supply chain

The White House on Thursday unveiled a plan to levy steep duties on certain imported patented medicines as part of a bid to force greater domestic pharmaceutical production and win lower drug prices for US patients.

According to Bloomberg, the executive action authorises tariffs of up to 100% on branded drugs manufactured in countries that do not have tariff arrangements with the United States when those products are sold by companies that have not agreed to most‑favoured‑n...

ation pricing with the administration. The White House said duties on goods from some larger manufacturers will begin in 120 days, while imports from smaller firms will be subject to levies after 180 days. Bloomberg also reported that generic medicines are initially exempt but will be reviewed within a year, leaving open the prospect of future duties.

The move largely preserves carve‑outs for firms that already struck deals with the administration. According to Axios, 13 major companies previously agreed to most‑favoured‑nation pricing arrangements after pressure from the White House, and those accords have shielded many big drugmakers from the new penalties. Stat News and other outlets noted that companies pledging to build manufacturing capacity in the United States can reduce the charge on their imports to 20%, and those that both onshore production and accept MFN pricing would pay no tariff. The White House described the tariff‑free window as lasting through the end of the current term; Bloomberg reported that exemption would remain in place through January 20, 2029, while the Irish Times cited a January 29, 2029, expiry in its account.

The administration also set out national‑level caps for imports from economies that maintain trade arrangements with Washington: the European Union, Japan, South Korea, Switzerland and Liechtenstein were identified as qualifying for a 15% cap, with Britain to face a lower rate, Reuters and Euronews reported. Euronews added that the UK government says it secured a temporary 0% rate for British medicines for at least three years.

The tariffs emerge from a Commerce Department investigation launched in April 2025 under Section 232 of the Trade Expansion Act, the law that permits the president to impose import restrictions on grounds of national security. AP noted that the order builds on longstanding White House rhetoric framing foreign dependence for drug supply as a security risk and comes on the anniversary of past large tariffs; AP also said the administration signalled a phased escalation that could see charges rise toward 100% over time if companies do not comply.

Industry groups have warned of practical consequences. Trade and supply‑chain associations cautioned that steep import duties could disrupt complex global production networks, aggravate shortages and push costs higher for American consumers. The Los Angeles Times highlighted how drug pricing in the United States is determined through intricate negotiations among insurers, pharmacy benefit managers and manufacturers, meaning any additional import costs may not translate immediately into higher shelf prices but could feed through to increased copayments or insurance premiums over time.

Analysts put the potential scope of the policy into perspective. The Irish Times cited an estimate by Veda Partners suggesting the full 100% tariff might apply to roughly $12 billion of goods , under 5% of total US pharmaceutical imports in 2025 , indicating that, because of the exemptions and prior agreements, the heaviest penalties would fall mainly on smaller manufacturers and ingredient suppliers based in production hubs such as China, India and Singapore, as Axios observed.

The administration’s action adds to a series of protectionist measures from the same White House. Legal challenges earlier this year saw the Supreme Court rule that certain global tariffs were unconstitutional, though duties imposed under Section 232 on other sectors remained intact. The new pharmaceutical measures sit alongside moves to tighten and simplify metal tariffs, signalling a broader trade posture that ties industrial policy and price‑setting leverage to domestic reshoring.

For patients and payers, the immediate effects are uncertain. Observers quoted by Stat and the Los Angeles Times suggested that while the policy is intended to spur onshoring and reduce long‑term dependence on foreign production, in the near term companies will face a choice between absorbing higher import costs or seeking to pass them on through the health‑care system. The White House framed the package as a lever to secure lower prices and greater manufacturing investment in the United States; industry representatives and trade analysts warned it could complicate already fragile supply chains and raise costs before any domestic capacity expansion meaningfully alters markets.

Source: Noah Wire Services